BEPRIDIL HYDROCHLORIDE

US Previously Marketed

First approved in 1990

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H34N2O.ClH.H2O
Molecular Weight	421.016
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3

InChI

InChIKey=UEECHQPWQHYEDE-UHFFFAOYSA-N

InChI=1S/C24H34N2O.ClH.H2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H;1H2

HIDE SMILES / InChI

Molecular Formula	C24H34N2O
Molecular Weight	366.5396
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/vascor-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It has inhibitory effects on both the slow calcium and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. It is used to treat hypertension (high blood pressure), angina (chest pain), sustained atrial fibrillation and tachyarrhythmia. The most common side effects were upper gastrointestinal complaints (nausea, dyspepsia or GI distress), diarrhea, dizziness, asthenia and nervousness. Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-secretase (BACE) 5 Target ID: CHEMBL2111390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Inhibitor 8297	6.0 µM [IC50]
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Modulator 828
potassium sodium-activated channel subfamily T member 1 3 Target ID: 57582.0 Gene Symbol: KCNT1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16876206	Inhibitor 8297	1.0 µM [IC50]
Voltage and receptor operated calcium channels 3 Target ID: Voltage and receptor operated calcium channels Sources: http://www.rxlist.com/vascor-drug.htm	Blocker 537

Conditions

Condition	Modality	Highest Phase	Product
Chronic stable angina 10 Sources: http://www.rxlist.com/vascor-drug.htm	Primary	Approved 8429	BEPRICOR Approved Use Bepridil hydrochloride is indicated for the treatment of chronic stable angina (classic effort-associated angina).
Hypertension 567 Sources: https://www.drugs.com/mtm/bepridil.html	Primary	Approved 8429	BEPRICOR Approved Use Bepridil is used to treat hypertension (high blood pressure) and to treat angina (chest pain).
Atrial fibrillation 131 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8429	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.
Tachyarrhythmia 17 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8429	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.

C_max

Value	Dose	Co-administered	Analyte	Population
806 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
38.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3875635			BEPRIDIL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years n = 44 Health Status: unhealthy Condition: angina Age Group: 34-77 years Sex: M+F Population Size: 44 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Weakness, Lightheadedness... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Lightheadedness (1 patient) Syncopal attack (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years n = 43 Health Status: unhealthy Condition: angina Age Group: 39-84 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Electrocardiogram QTc interval prolonged (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years n = 46 Health Status: unhealthy Condition: angina Age Group: 43-80 years Sex: M+F Population Size: 46 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Diarrhea (1 patient) Anorexia (1 patient) Bigeminy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years n = 33 Health Status: unhealthy Condition: angina Age Group: 63.5 years Sex: M+F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (1 patient) Bradycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years n = 29 Health Status: unhealthy Condition: angina Age Group: 64.6 years Sex: M+F Population Size: 29 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (grade 5, 1 patient) Bradycardia (1 patient) Electrocardiogram QTc interval prolonged (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

AEs

AE	Significance	Dose	Population
Lightheadedness	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years n = 44 Health Status: unhealthy Condition: angina Age Group: 34-77 years Sex: M+F Population Size: 44 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Syncopal attack	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years n = 44 Health Status: unhealthy Condition: angina Age Group: 34-77 years Sex: M+F Population Size: 44 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Weakness	2 patients Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years n = 44 Health Status: unhealthy Condition: angina Age Group: 34-77 years Sex: M+F Population Size: 44 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Electrocardiogram QTc interval prolonged	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years n = 43 Health Status: unhealthy Condition: angina Age Group: 39-84 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Anorexia	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years n = 46 Health Status: unhealthy Condition: angina Age Group: 43-80 years Sex: M+F Population Size: 46 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bigeminy	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years n = 46 Health Status: unhealthy Condition: angina Age Group: 43-80 years Sex: M+F Population Size: 46 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Diarrhea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years n = 46 Health Status: unhealthy Condition: angina Age Group: 43-80 years Sex: M+F Population Size: 46 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Nausea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years n = 46 Health Status: unhealthy Condition: angina Age Group: 43-80 years Sex: M+F Population Size: 46 Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bradycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years n = 33 Health Status: unhealthy Condition: angina Age Group: 63.5 years Sex: M+F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years n = 33 Health Status: unhealthy Condition: angina Age Group: 63.5 years Sex: M+F Population Size: 33 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Bradycardia	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years n = 29 Health Status: unhealthy Condition: angina Age Group: 64.6 years Sex: M+F Population Size: 29 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Electrocardiogram QTc interval prolonged	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years n = 29 Health Status: unhealthy Condition: angina Age Group: 64.6 years Sex: M+F Population Size: 29 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	grade 5, 1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years n = 29 Health Status: unhealthy Condition: angina Age Group: 64.6 years Sex: M+F Population Size: 29 Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	inhibitor 1852 substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2E1 882	CYP1A2 1054 P-gp 1537 BCRP 561

Drug as perpetrator

Target	Modality	Activity
CYP2A6 739	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19702529/	yes
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/32906709/	yes

Drug as victim

Target	Modality	Activity
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28210973/	no
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
P-gp 1537	substrate 3367 Sources: https://www.futuremedicine.com/doi/abs/10.1517/14622416.2.4.401	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY565364	https://www.001chemical.com/chem/64706-54-3
3B Scientific (Wuhan) Corp	3B2-0571	http://www.3bsc.com/index/pro_info.php?id=19927
AHH Chemical co.,ltd	API-1541	http://www.ahhchemical.com/product/API-1541.html
AK Scientific, Inc. (AKSCI)	K042	http://www.aksci.com/item_detail.php?cat=K042
Achemo Scientific Limited	AC-11145	http://www.achemo.com/search/?Keyword=64706-54-3
Angel Pharmatech	AG121309	http://www.angelpharmatech.com/64706-54-3.html
BLD Pharm	BD116381	http://www.bldpharm.com/products/64706-54-3.html
CSNpharm	CSN10416	https://www.csnpharm.com/products/bepridil.html
ChemMol	30105085	http://www.chemmol.com/chemmol/30105085.html
ChemMol	99124623	http://www.chemmol.com/chemmol/99124623.html
Chemspace	CSSB00000047941	https://chem-space.com/CSSB00000047941
Debye Scientific	DB-054717	http://www.debyesci.com/cas_64706-54-3.html
Finetech	FT-0630749	http://www.finetechnology-ind.com/prod/detail/pub/64706-54-3.html
Glentham Life Sciences	GP4395	http://www.glentham.com/products/product/GP4395/
Lab Network	LN00330174	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00330174
Molcore	MC565364	https://www.molcore.com/product/64706-54-3
Smolecule	S520991	http://www.smolecule.com/products/s520991
Smolecule	S772535	https://www.smolecule.com/products/s772535
THE BioTek	bt-261730	https://www.thebiotek.com/product/inhibitors/bt-261730
THE BioTek	bt-311849	https://www.thebiotek.com/product/others/bt-311849
Vesino Industrial Co Ltd	VA10387	http://www.vsnchem.com/goto/product/23859/
abcr GmbH	AB542520	http://www.abcr.com/shop/en/AB542520

PubMed

Title	Date	PubMed
Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens.	1992 Apr	1390333
Biliary drug lithiasis: dipyridamole gallstones.	1992 Nov 28	1360065
Is cytotoxic cellular edema real? The effect of calcium ion on water homeostasis in the rat heart.	2001	12213994
A quinolone alkaloid with antioxidant activity from the aleurone layer of anthocyanin-pigmented rice.	2001 Dec	11754619
[Bepridil inhibition on the delayed rectifier K+ currents in thyroxine induced hypertrophied guinea pig ventricular myocytes].	2001 Jul	12585077
Electron spin resonance assessment of the antioxidant potential of medicinal plants. Part I. Contribution of anthocyanosides and flavonoids to the radical scavenging ability of fruit and herbal teas.	2001 Jul-Aug	11693734
Evaluation of the absorption, excretion, and metabolism of the antihypertensive agent RWJ-26899 in male and female CR Wistar rats and Beagle dogs.	2001 Jul-Sep	11695715
Antioxidant properties of methanolic extracts from several ear mushrooms.	2001 Nov	11714344
Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities.	2001 Nov-Dec	11911276
Antioxidative components from the aerial parts of Lactuca scariola L.	2001 Oct	11693545
Effect of calcium antagonists, calcium channel blockers and calmodulin inhibitors on the growth and encystation of Entamoeba histolytica and E. invadens.	2001 Oct	11688889
DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants.	2001 Oct	11642334
Comparison of radical scavenging effect, inhibition of microsomal oxygen free radical generation, and serum lipoprotein oxidation of several natural antioxidants.	2002 Apr 10	11929315
Antioxidative activity and safety of the 50 ethanolic extract from red bean fermented by Bacillus subtilis IMR-NK1.	2002 Apr 10	11929313
Antioxidant functions of selected allium thiosulfinates and S-alk(en)yl-L-cysteine sulfoxides.	2002 Apr 24	11958610
On-line HPLC-DPPH screening method for evaluation of radical scavenging phenols extracted from apples (Malus domestica L.).	2002 Apr 24	11958609
Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.	2002 Aug	12128170
Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil.	2002 Aug 23	12060657
Antagonistic effects of 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 on L-type Ca2+ channels and Na+/Ca2+ exchange in enterocytes from Atlantic cod (Gadus morhua).	2002 Feb	11854099
Antioxidant capacities of ten edible North American plants.	2002 Feb	11807968
Interaction of digoxin with antihypertensive drugs via MDR1.	2002 Feb 15	11895100
Antioxidant effects of 1,5-anhydro-D-fructose, a new natural sugar, in vitro.	2002 Jan	11842320
Role of Na(+)-Ca(2+) exchanger after traumatic or hypoxic/ischemic injury to spinal cord white matter.	2002 Jan-Feb	14588286
Antioxidants from the bark of Burkea africana, an African medicinal plant.	2002 Mar	11933117
Free radical scavenging activity of red ginseng aqueous extracts.	2002 Mar 20	11882354
Free radical studies of ellagic acid, a natural phenolic antioxidant.	2002 Mar 27	11902978
Antioxidant properties of ferulic acid and its related compounds.	2002 Mar 27	11902973
Identification of radical scavengers in sweet grass (Hierochloe odorata).	2002 May 8	11982419
Assessment of pro-oxidant activity of foods by kinetic analysis of crocin bleaching.	2002 May 8	11982396
Na+/Ca2+ exchanger in Na+ efflux-Ca2+ influx mode of operation exerts a neuroprotective role in cellular models of in vitro anoxia and in vivo cerebral ischemia.	2002 Nov	12502588
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.	2002 Nov	12419934
Na(+)/Ca(2+) exchanger in porcine oocytes.	2002 Oct	12297528
Possible role of calcium ions, calcium channels and calmodulin in excystation and metacystic development of Entamoeba invadens.	2002 Sep	12172816
[Successful hybrid therapy combined with oral bepridil and ICD in a patient with amiodarone refractory life-threatening ventricular tachyarrhythmia associated with ischemic cardiomyopathy].	2002 Sep 1	12235963
Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".	2003 Apr-Jun	12877575
Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.	2003 Aug 15	12914884
A case of bepridil induced interstitial pneumonitis.	2003 Dec	14617550
Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP.	2003 Dec 17	14684870
Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.	2003 Feb	12557283
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.	2003 Jan	12687836
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.	2003 Jan	12520144
Detection of proarrhythmia in the female rabbit heart: blinded validation.	2003 Mar	12716112
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.	2003 Nov 17	14612892
Sodium-calcium exchange influences the response to endothelin-1 in lens epithelium.	2003 Sep	12887970
Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers.	2004	14979606
Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock.	2004 Feb	14716203
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.	2004 Feb 20	14975710
Atrial fibrillatory frequency, atrial fibrillatory rate, or atrial cycle length--does it matter?	2004 Jul 1	15219531
Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists.	2004 Jul 16	15203145
Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats.	2004 Mar	14975699

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 200 mg once a day. Maintenance dose: 300-400 mg once a day.

Route of Administration: Oral

In Vitro Use Guide

In APP-overexpressing HEK293 cells lower Ab38, Ab40 and Ab42 generation was detected after Bepridil treatment (30 uM) for 16 h.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:18:52 GMT 2023` Edited by `admin` on `Fri Dec 15 15:18:52 GMT 2023`
Record UNII	4W2P15D93M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEPRIDIL HYDROCHLORIDE

Official Name

English

Bepridil hydrochloride monohydrate [WHO-DD]

Common Name

English

1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, MONOHYDROCHLORIDE, MONOHYDRATE

Common Name

English

BEPRIDIL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

CERM 1978

Code

English

BEPADIN

Brand Name

English

NSC-758390

Code

English

UNICORDIUM

Brand Name

English

1-[2-(N-Benzylanilino)-1-(isobutoxymethyl)ethyl]-pyrrolidine monohydrochloride monohydrate

Systematic Name

English

BEPRIDIL HYDROCHLORIDE [MART.]

Common Name

English

BEPRIDIL HYDROCHLORIDE MONOHYDRATE

Common Name

English

BEPRIDIL HYDROCHLORIDE [VANDF]

Common Name

English

CORDIUM

Brand Name

English

BEPRIDIL HYDROCHLORIDE HYDRATE

Common Name

English

BEPRIDIL HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

BEPRIDIL HYDROCHLORIDE MONOHYDRATE [MI]

Common Name

English

CERM-1978

Code

English

VASCOR

Brand Name

English

BEPRIDIL HYDROCHLORIDE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333